STAT+: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes
The unilateral decision by Peter Marks, a top FDA official, to approve a gene therapy for Duchenne muscular dystrophy looks even more surprising on a close examination.
The unilateral decision by Peter Marks, a top official at the Food and Drug Administration, to , a treatment for Duchenne muscular
